12:00 AM
Feb 27, 2012
 |  BC Week In Review  |  Company News  |  Deals

Enanta, Novartis deal

Enanta granted Novartis exclusive, worldwide rights to develop and commercialize preclinical HCV product EDP-239. The HCV non-structural protein 5A (NS5A) inhibitor has IND...

Read the full 104 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >